HCA Healthcare Inc (HCA): analysis and signal as of September 2, 2026
In short
The model assigns HCA Healthcare a weak signal, with a score of 3,0 and a vote of 3/3. The deterioration in revenue quality, linked to the rise in uninsured patients and dependence on directed Florida Medicaid payments, explains this caution despite a massive share repurchase.
- Current signal
- weak (vote 3/3)
- Deterministic score
- +3.0 → signal expected by the scale : moderate (September 10, 2026)
- Layers
- fundamentals : negative, price : neutral, risks : negative
Triggered rules
| Rule | Weight |
|---|---|
| penalizes an asset whose net debt/EBITDA exceeds the threshold, and the use of leverage (margin/lombard) | -2.5 |
| favors a high and durable return on invested capital (ROIC), a marker of a lasting moat | +2.0 |
| favors (GARP) a stock whose PEG is below 1, growth not yet paid for | +1.5 |
| favors robust fundamental health (high Piotroski F-Score) | +1.5 |
| penalizes direct holding of US securities in a CTO (US estate tax at death), favors a UCITS ETF domiciled in IE | -1.0 |
| favors high gross profitability (gross profit / assets), a robust predictor of returns | +1.0 |
| moderately favors a positive 12-1 month momentum (tailwind), BUT guardrail: costly rotation, long-term reversal, momentum crashes, a conviction signal, not a rotation trigger | +0.5 |
Thesis
HCA Healthcare remains an efficient operator, supported by its scale, a high ROIC and a massive share repurchase. Revenue quality has nevertheless deteriorated with the growth in uninsured patients and dependence on directed Florida Medicaid payments. The stock also shows an average correlation of 0,06, a source of diversification. The model nonetheless issues only a weak signal as long as the payer mix and the September catalysts are not clarified.
Bull case
The group repurchased 2 789,6 M USD of its own shares as of 30/06, or 2,86 % of the capital, including 1 968,9 M USD in the second quarter alone. The consensus built from 46 analysts sits about 13 % above the 02/09 price, set at 402,02 USD. The Piotroski scores and gross profitability come out high. Finally, the stock's average correlation of 0,06 provides a measured diversification contribution.
Bear case
Net profit grows by +2,8 % while earnings per share gains +11,6 %. The gap comes from the share repurchase and public payments, not from operations. About 1,77 Md USD of second-quarter revenue falls under directed or supplementary Medicaid payments, including 1,372 Md for Florida and about 400 M USD from other schemes. These flows remain exposed to political risk after the guidance cut announced on 14/07, which could reach 700 M USD. High debt earns a penalty of -2,5 in the rating rules, the price trades 11 % below its 200-session moving average and a shareholder investigation led by Kirby McInerney remains pending.
Scenarios
The bullish scenario, weighted at 30 %, rests on a clarification of the payer mix and on a return of the price above its 200-session moving average. The central scenario, weighted at 50 %, describes a move with no clear trend up to the Wells Fargo event of 09/09 and the ex-dividend date of 16/09, for performance close to zero. The bearish scenario, weighted at 20 %, assumes a new guidance cut or Medicaid cuts in Florida, accompanied by a weekly close in clear decline.
Risks
The main risks remain political and regulatory. About 1,77 Md USD of second-quarter revenue depends on directed or supplementary Medicaid payments, including 1,372 Md tied to Florida, already targeted by a guidance cut that could reach 700 M USD on 14/07. The group's high debt is a second point of weakness, penalized at -2,5 by the rating rules. A shareholder investigation led by Kirby McInerney is pending and the price trades 11 % below its 200-session moving average. A new guidance cut would weaken the thesis.
Market positioning (short sellers)
- Short interest / shares outstanding
- 4.25 %
- Days to cover
- 5.56
- Settlement date
- 2026-08-14
- Source
- FINRA (disseminated on 2026-08-26)
Upcoming catalysts
| Date | Description |
|---|---|
| Third quarter 2026 results expected |
Signal history (last 12 months)
| Date | Signal | New fact |
|---|---|---|
| weak (3/3) | No new dated fact since the verdict of 2026-08-31. The updated data of 02/09 repeat the same elements: results and guidance of 14/07, short interest as of 14/08, investigations from July and August. The 02/09 session, down 2,79 %, does not constitute a new fundamental fact, nor do the mentions of possible expiry. This content is a personal analysis and does not constitute investment advice. | |
| weak (single draw, outside the three-draw protocol) | unchanged |
Frequently asked questions
Why does the signal remain weak despite the massive share repurchase?
The 2 789,6 M USD repurchase as of 30/06, including 1 968,9 M USD in the second quarter, shows the group's financial strength. The model nevertheless prioritizes revenue quality. About 1,77 Md USD of quarterly revenue depends on directed or supplementary Medicaid payments, a flow exposed to political risk after a guidance cut that could reach 700 M USD. The signal therefore remains weak.
Why does earnings per share grow faster than net profit?
Net profit gains +2,8 % while earnings per share rises by +11,6 %. The difference does not come from operations. It is explained by the reduction in the number of shares following the repurchases, 2,86 % of the capital as of 30/06, and by public payments. The model sees this as a drag on earnings quality, because the growth does not reflect an improvement in operations.
What role does Florida play in the group's results?
Florida concentrates the main stake. Of 1,77 Md USD in second-quarter revenue from directed or supplementary Medicaid payments, 1,372 Md comes from this state, complemented by about 400 M USD from other schemes. After the 14/07 guidance cut, which could reach 700 M USD, any local budget cut would directly weaken this revenue and the central scenario, weighted at 50 %.
Which events frame the stock in September?
Two events structure September: Wells Fargo on 09/09 and the ex-dividend date of 16/09. Clarification of the payer mix is another decisive criterion for the signal. These elements determine whether the bullish scenario, weighted at 30 %, or the bearish scenario, weighted at 20 %, gains the advantage over the 50 % central scenario, which describes performance close to zero.
What does the average correlation of 0,06 mean for the stock?
This average correlation of 0,06 reflects a move loosely tied to that of the other stocks tracked by the model. HCA therefore provides a measured diversification contribution, with no notable duplication of the universe already covered. This point feeds the bullish argument, even if the overall signal remains weak as long as the payer mix is not clarified.
Sources
The official filings below are the issuer's own, matched to this stock by its identifier (LEI, CIK or ISIN). The figures quoted above come from an automated arbitration: they have not been re-checked one by one.
- — 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; 8.01 Other Events (SEC · 8-K)
- — 10-Q (SEC · 10-Q)
- — 2.02 Results of Operations and Financial Condition; 7.01 Regulation FD Disclosure; 8.01 Other Events; 9.01 Financial Statements and Exhibits (SEC · 8-K)
- — 2.02 Results of Operations and Financial Condition; 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits (SEC · 8-K)
- — 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers (SEC · 8-K)
Automated AI analysis: limitations and transparency
- This content is an automated analysis produced using artificial intelligence. Personal analysis for information purposes — no personalised investment advice. MMR content consists of general research. It does not take account of your financial circumstances, objectives or risk tolerance. Data, analyses and results, including those produced using artificial intelligence, may contain errors, be incomplete or become outdated. No return or outcome is guaranteed. All investments carry a risk of partial or total loss of capital. Past performance and simulations do not predict future results. Before making any decision, check information against original sources and, where necessary, consult an authorised professional. You remain responsible for your investment decisions. This notice does not exclude or limit any liability that cannot legally be excluded or limited.
- Tool and analysis: QDNA, Aurélien Ambert.
- Analysis (arbitration) completed on September 2, 2026; this page was completed on September 3, 2026 at 23:51 (UTC).
- Interests: no position in the stock analysed (HCA) is recorded in the data consulted on (UTC). This does not confirm the absence of holdings or other interests. The situation at the analysis publication date has not been reconstructed.
- This declaration covers only recorded positions in this stock; it is not an exhaustive verification of other interests or remuneration.
- Methodology: analysis chain, score formula and scale described on the public methodology page.
- Analysis horizon: 2035.
See also
- Neighbouring stock in the same sector: AbbVie, Inc. (ABBV)
- All analysed stocks
- Public methodology